A study of AEOL 10150 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A study of AEOL 10150 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

Planning
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs AEOL 10150 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2016 According to an Aeolus Pharmaceuticals media release, the U.S. Food & Drug Administration received clearance to initiate phase I studies with AEOL 10150 in healthy normal volunteers.
    • 15 Aug 2016 According to Aeolus Pharmaceuticals media release, planned initiation date changed from 1 Jul 2016 to 1 Jul 2017.
    • 15 Aug 2016 According to Aeolus Pharmaceuticals media release, company is preparing for IND submissions to the FDA and initiating clinical study over the next two quarters.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top